礼来公司CEO表示，开展阿尔茨海默病预防及其他脑部疾病的研究。 ...

礼来公司CEO表示，他们不提高药品价格很重要。 ...

Eli Lilly & Co. LLY shares staged their sharpest single-day rally in nearly 25 years Thursday, after unveiling data from a pivotal trial that could cement its leadership in a weight-loss drug market projected to more than triple in size by 2030. The stock surged, closing the day up 14.36% to $839.96, marking its best performance since June 2000.In a Thursday note, Goldman Sachs analyst Asad Haider, CFA said Eli Lilly's first Phase 3 trial of orforglipron — a once-daily oral treatment for type 2 diabetes and ...

Eli Lilly has a plan to dominate the GLP-1 weight loss drug market -- and it's succeeding.It's Thursday morning, 11:50 a.m. ET -- and Eli Lilly (LLY 16.30%) stock is off to the races!This morning, the Indianapolis-based pharmaceutical giant announced that its new GLP-1 weight loss pill, orforglipron, has "demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful [ACHIEVE-1] Phase 3 trial."Lilly shares are up 14.2% in response to the ...

Eli Lilly shares jumped 15% after a clinical trial of its experimental pill showed it helped patients with Type 2 diabetes lose weight at levels comparable to leading injectable medications like Ozempic.The mid-stage trial results announced on Thursday by the pharmaceutical giant showed that patients taking orforglipron lost an average of 16 pounds — or 7.9% of their body weight — over a 26-week period.That outcome compares favorably to Novo Nordisk’s widely prescribed Ozempic, which helped diabetic patient ...

文章核心观点 - 礼来公司因减肥药物3期试验结果积极，股价有望创2023年8月以来最佳单日表现，期权交易活跃且市场情绪有转变 [1][3][4] 股价表现 - 礼来公司股价上涨13.4%，至838.48美元，有望创2023年8月以来最佳单日表现 [1] - 今日股价反弹使礼来股票从4月初的熊市缺口完全恢复，并使该股在2025年重回正区间 [2] - 礼来股票14日相对强弱指数（RSI）为30，处于“超卖”区域，股价在840美元水平面临熟悉压力 [2] 药物试验 - 礼来公司减肥药物orforglipron 3期试验结果积极，最高剂量使患者体重减轻近8%，并降低2型糖尿病患者血糖 [1] 期权交易 - 今日礼来公司期权交易中，已有45000份看涨期权和35000份看跌期权成交，是该股整体日均期权交易量的8倍 [3] - 4月到期的800看跌期权和900看涨期权最受欢迎，两者均有新头寸开仓 [3] 市场情绪 - 礼来公司在国际证券交易所（ISE）、芝加哥期权交易所（CBOE）和纳斯达克OMX PHLX（PHLX）的10日看跌/看涨成交量比率为1.01，高于过去一年87%的读数，显示过去两周看跌期权的买入速度高于往常 [4] - 对看涨期权的偏好显示市场情绪发生转变 [4]

INDIANAPOLIS, April 17, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2025 financial results on May 1, 2025. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance. The conference call will begin at 10 a.m. Eastern time. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at https://invest ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024.Eli Lilly on Thursday said its daily obesity pill met the company's goals in the first of several late-stage trials, helping Type 2 diabetes patients lower their blood sugar and body weight and showing safety on par with popular injections on the market. The trial results are among the pharmaceutical industry's most closely watched studies of the year, as they bring Eli Lilly's experimental ...

Orforglipron is the first small molecule GLP-1 to successfully complete a Phase 3 trial, lowering A1C by an average of 1.3% to 1.6% across doses The investigational once-daily oral pill reduced weight by an average 16.0 lbs (7.9%) at the highest dose in a key secondary endpoint The overall safety and tolerability profile of orforglipron in ACHIEVE-1 was consistent with injectable GLP-1 therapies   INDIANAPOLIS, April 17, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline ...